A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Status:
RECRUITING
Trial end date:
2032-06-25
Target enrollment:
Participant gender:
Summary
Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)